Current clinical guidelines regarding the monitoring of treatment in advanced lung cancer do not recommend the routine determination of biomarkers.6 To evaluate CEA and LDH levels in relation to treatment response, a retrospective follow‐up study in a large cohort of patients with advanced NSCLC receiving first‐line platinum‐based chemotherapy, was conducted. Here, CEACAM5 is linked to non-small cell lung carcinoma.